Our latest product data sheet is available for download, it contains expression data from a variety of evaluations that used GS selection as part of the CHO SOURCE GS null CHO K1 expression system to generate recombinant proteins.
Alternatively, see our technical information:
As the final product will be administered to patients, the manufacture of biotherapeutic products is a highly regulated process. As a core part of the manufacturing process, the CHO cell host must be well characterised and safe for the manufacture of biotherapeutics.
When considering which cell line to use for the manufacture of biotherapeutics, the safety profile of the cell line is a core concern. To address these concerns review our traceability information which includes reference to the following:
During full evaluation of the cell line we can also make available a more extensive traceability pack that includes:
To raise the bar in expected safety standards, we are the only provider of commercially available CHO cells to have published the whole genome sequence of our cells. Eagle Genomics were commissioned to perform the high quality genome assembly and gold standard gene annotation.
Download the our annotated whole genome sequence data :
Download a copy of the document we sent to the MHRA prior to a meeting requesting Scientific Advice. This document includes:
Download our whitepaper on the role genome engineering has to play in the future of bioprocessing and biomanufacturing. This whitepaper discusses:
Read our tutorial that was published in GEN on how genome engineering has been used to remove host cell proteins that were co-purifying with a recombinant protein product and could not easily be removed through downstream processing approaches.